racial and ethnic differences in clinical outcomes among myeloma pts treated with car t therapy
Published 1 year ago • 290 plays • Length 6:13Download video MP4
Download video MP3
Similar videos
-
7:08
krina patel, md, msc, and christen dillard, md: racial and ethnic outcomes in car t for mm
-
4:01
what are the differences between car t-cell therapy and bispecific antibodies?
-
3:52
is car t-cell therapy being used to treat newly diagnosed multiple myeloma?
-
3:47
what is car t-cell therapy?
-
5:34
myeloma university | the patient journey and car-t therapy management in multiple myeloma.
-
15:50
understanding car t therapy: a groundbreaking approach to myeloma treatment
-
4:25
updated results from cartitude-1: phase 1b/2study of cilta-cel in pts with rr multiple myeloma
-
48:06
the latest insights on immune therapies in myeloma | 2023 imf patient and family seminar
-
8:06
clinical activity of bms-986393, a car t cell therapy directed at gprc5d, in pts with rrmm
-
4:37
what is car t cell therapy?
-
4:20
what were the results of the determination trial presented at asco and eha?
-
1:47
clinical outcomes of patients with r/r multiple myeloma listed for treatment with car-t therapy
-
0:57
monoclonal antibodies and car t-cell therapy #knowmyeloma
-
7:49
idecabtagene vicleucel, a bcma-directed car t cell therapy, in rrmm: updated karmma results
-
1:45
comparing salvage transplantion to car t-cell therapy for treating relapsed multiple myeloma
-
10:06
safety and efficacy of fully human bcma car t cells in combination with a gamma secretase inhibitor
-
9:34
neurologic adverse effects in pts with mm treated with cilta-cel in cartitude-2
-
6:28
phase i crb-402 study of the bcma-targeted car t cell therapy bb21217 in pts w/rr multiple myeloma
-
5:42
comparison of outcomes with cilta-cel in cartitude-1 vs rw soc for pts w/ triple-class exposed rrmm